Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
- Author:
Da Som JEON
1
;
Ho Cheol KIM
;
Se Hee KIM
;
Tae-Jung KIM
;
Hong Kwan KIM
;
Mi Hyung MOON
;
Kyongmin Sarah BECK
;
Yang-Gun SUH
;
Changhoon SONG
;
Jin Seok AHN
;
Jeong Eun LEE
;
Jeong Uk LIM
;
Jae Hyun JEON
;
Kyu-Won JUNG
;
Chi Young JUNG
;
Jeong Su CHO
;
Yoo-Duk CHOI
;
Seung-Sik HWANG
;
Chang-Min CHOI
;
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2023;55(1):103-111
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials and Methods:The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Results:We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
Conclusion:In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.
